Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences

Group 1 - Eli Lilly and Company (NYSE: LLY) is acquiring Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on innovative oral therapies for inflammatory-mediated diseases [1][2] - The acquisition involves purchasing all outstanding shares of Ventyx for $14.00 per share, totaling an equity value of approximately $1.2 billion [2] - The transaction is expected to close in the first half of 2026, pending approval from Ventyx stockholders and regulatory approvals [2][3] Group 2 - The acquisition price represents a premium of around 62% over the 30-day volume-weighted average trading price of Ventyx's common stock as of January 5, 2026 [3] - Eli Lilly develops a wide range of pharmaceutical products, including those in oncology, diabetes, immunology, and neuroscience [3]